Epax will be investing $35 million over the next two years to increase its capacity and innovate in the omega-3 sector.
Photo © iStockphoto.com/ evemilla
Epax (à lesund, Norway) will be investing $35 million over the next two years to increase its capacity and innovate in the omega-3 sector. As part of the investment, the company will expand the capacity of its main production facility in à lesund for a more than 50% increase in output by 2021, and a new manufacturing facility will provide raw materials for new and specialized marine ingredients. Epax intends to implement a new distillation process that increases EPA and DHA concentration without triggering oxidation, producing concentrations as high as 70% by weight.
“As a leading producer of highly concentrated omega-3, and a company with a proud history of innovation, we have a responsibility to push the limits of what is possible. This substantial investment will create new possibilities for the marine ingredients sector in terms of concentration, purity and quality,” Bjørn Refsum, CEO of Epax, in a press release. “We’re particularly excited about our new distillation process, which we believe is the most effective and environmentally friendly way to achieve high levels of EPA and DHA without creating unwanted by-products and waste materials.”
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.